|
US20070077256A1
(en)
|
1999-11-19 |
2007-04-05 |
Los Angeles Biomedical Research Institute |
Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
|
|
US8541008B2
(en)
*
|
1999-11-19 |
2013-09-24 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Pharmaceutical compositions and methods to vaccinate against candidiasis
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
DK1354034T3
(da)
|
2000-11-30 |
2008-03-25 |
Medarex Inc |
Transgene transchromosomale gnavere til fremstilling af humane antistoffer
|
|
DE60227067D1
(de)
*
|
2001-05-11 |
2008-07-24 |
Kirin Pharma Kk |
Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
|
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
KR101531400B1
(ko)
|
2003-06-27 |
2015-06-26 |
암젠 프레몬트 인코포레이티드 |
상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
|
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
|
US7625549B2
(en)
|
2004-03-19 |
2009-12-01 |
Amgen Fremont Inc. |
Determining the risk of human anti-human antibodies in transgenic mice
|
|
US20080026457A1
(en)
|
2004-10-22 |
2008-01-31 |
Kevin Wells |
Ungulates with genetically modified immune systems
|
|
ES2679282T3
(es)
*
|
2004-10-22 |
2018-08-23 |
Revivicor Inc. |
Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
|
|
EP1851245B1
(en)
|
2005-01-26 |
2012-10-10 |
Amgen Fremont Inc. |
Antibodies against interleukin-1 beta
|
|
WO2006113643A2
(en)
|
2005-04-20 |
2006-10-26 |
Amgen Fremont Inc. |
High affinity fully human monoclonal antibodies to interleukin-8 and epitopes for such antibodies
|
|
WO2006117699A2
(en)
*
|
2005-04-29 |
2006-11-09 |
Innate Pharma |
Transgenic animals and methods of making recombinant antibodies
|
|
NL1029605C2
(nl)
*
|
2005-07-25 |
2007-01-26 |
Li-Te Chin |
Nieuwe uit menselijke kiemlijnsequenties gewonnen antilichaamstructuren.
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
EP2167669A2
(en)
|
2007-05-31 |
2010-03-31 |
Genmab A/S |
Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
|
|
EP2602323B1
(en)
|
2007-06-01 |
2018-02-28 |
Open Monoclonal Technology, Inc. |
Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies
|
|
LT2346994T
(lt)
|
2008-09-30 |
2022-03-10 |
Ablexis, Llc |
Knock-in pelė, skirta chimerinių antikūnų gamybai
|
|
DK2348827T3
(en)
|
2008-10-27 |
2015-07-20 |
Revivicor Inc |
IMMUNICIPLY COMPROMATED PETS
|
|
EP3028565B1
(en)
|
2009-07-08 |
2017-09-27 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
NO2719708T3
(enExample)
|
2009-11-13 |
2018-03-24 |
|
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
SMT201900372T1
(it)
|
2010-02-08 |
2019-09-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
KR102004106B1
(ko)
|
2010-03-31 |
2019-07-25 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
SI2480676T1
(sl)
|
2010-06-22 |
2016-10-28 |
Regeneron Pharmaceuticals, Inc. |
Hibridna mišja lahka veriga
|
|
RU2612903C2
(ru)
*
|
2010-08-02 |
2017-03-13 |
Ридженерон Фармасьютикалз, Инк. |
Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
|
|
JP2013540694A
(ja)
|
2010-08-06 |
2013-11-07 |
ウー３・フアルマ・ゲー・エム・ベー・ハー |
Ｈｅｒ３結合剤の前立腺治療における使用
|
|
TWI636993B
(zh)
|
2010-10-27 |
2018-10-01 |
安美基公司 |
Ｄｋｋ１抗體及使用方法
|
|
EP2704743B1
(en)
*
|
2011-05-04 |
2020-03-11 |
Omeros Corporation |
Compositions for inhibiting masp-2 dependent complement acitivation
|
|
CN103998056B
(zh)
|
2011-07-22 |
2017-09-12 |
诺瓦蒂格姆疗法有限公司 |
用于接种抗金黄色葡萄球菌疫苗的方法和组合物
|
|
HUE068728T2
(hu)
|
2011-08-05 |
2025-01-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
JP2014531452A
(ja)
*
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
動物、レパートリーおよび方法
|
|
EP2757875B2
(en)
|
2011-09-19 |
2023-03-22 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
IN2014CN02113A
(enExample)
|
2011-09-21 |
2015-05-29 |
Fujirebio Kk |
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
PE20141937A1
(es)
|
2011-11-16 |
2014-12-18 |
Amgen Inc |
Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
MX378871B
(es)
|
2011-12-20 |
2025-03-10 |
Regeneron Pharma |
Ratones con cadena ligera humanizada.
|
|
KR102213535B1
(ko)
|
2012-03-16 |
2021-02-08 |
리제너론 파마슈티칼스 인코포레이티드 |
pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
|
|
EP3348140B1
(en)
|
2012-03-16 |
2020-12-30 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
CA2865644A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
JP5976380B2
(ja)
|
2012-04-27 |
2016-08-23 |
公益財団法人東京都医学総合研究所 |
ウロキナーゼ型プラスミノーゲンアクチベータートランスジェニックマウス
|
|
EP2858487B1
(en)
|
2012-06-12 |
2019-10-23 |
Regeneron Pharmaceuticals, Inc. |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
|
ES2728936T3
(es)
|
2013-01-25 |
2019-10-29 |
Amgen Inc |
Anticuerpos dirigidos contra CDH19 para melanoma
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
RS57582B1
(sr)
*
|
2013-02-20 |
2018-11-30 |
Regeneron Pharma |
Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
|
|
US20160122436A1
(en)
|
2013-03-15 |
2016-05-05 |
Amgen Research (Munich) Gmbh |
Single chain binding molecules comprising n-terminal abp
|
|
EA030005B1
(ru)
|
2013-03-15 |
2018-06-29 |
Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер |
Композиции и способы лечения грибковых и бактериальных патогенов
|
|
EP2970446A1
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Research (Munich) GmbH |
Antibody constructs for influenza m2 and cd3
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
WO2015049517A2
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
RU2016141307A
(ru)
|
2014-03-21 |
2018-04-24 |
Регенерон Фармасьютикалз, Инк. |
Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
|
|
AR101400A1
(es)
|
2014-07-31 |
2016-12-14 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido
|
|
CA2956471C
(en)
|
2014-07-31 |
2024-09-10 |
Amgen Res Munich Gmbh |
OPTIMIZED CONSTRUCTIONS OF SINGLE-CATENAL, BI-SPECIFIC, AND CROSS-SPECIFIC ANTIBODY
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
US11111314B2
(en)
|
2015-03-19 |
2021-09-07 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
AU2016250023B2
(en)
|
2015-04-17 |
2022-02-24 |
Amgen Research (Munich) Gmbh |
Bispecific antibody constructs for CDH3 and CD3
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
PT3411402T
(pt)
|
2016-02-03 |
2022-02-01 |
Amgen Inc |
Construtos de anticorpos biespecíficos engajadores de células t contra bcma e cd3
|
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
CN108883167A
(zh)
|
2016-03-09 |
2018-11-23 |
加州大学洛杉矶分校港口医学中心生物医学研究所 |
用于预防和治疗外阴阴道念珠菌病的方法和药剂盒
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
WO2017214089A1
(en)
|
2016-06-06 |
2017-12-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing antibodies with human lambda light chains
|
|
MA53935A
(fr)
|
2016-11-04 |
2021-12-22 |
Regeneron Pharma |
Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée
|
|
SG10202109874VA
(en)
|
2017-01-19 |
2021-10-28 |
Open Monoclonal Tech Inc |
Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
|
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
|
SG11201909547TA
(en)
|
2017-05-05 |
2019-11-28 |
Amgen Inc |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
|
PL3720279T3
(pl)
|
2017-12-05 |
2023-01-16 |
Regeneron Pharmaceuticals, Inc. |
Myszy posiadające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny oraz ich zastosowania
|
|
IL321479A
(en)
|
2017-12-11 |
2025-08-01 |
Amgen Inc |
Lengthy manufacturing process for bispecific antibody products
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
|
|
CN112771075A
(zh)
|
2018-07-30 |
2021-05-07 |
安进研发（慕尼黑）股份有限公司 |
结合至cd33和cd3的双特异性抗体构建体的延长施用
|
|
CN112512581B
(zh)
|
2018-08-03 |
2024-12-17 |
安进研发（慕尼黑）股份有限公司 |
针对cldn18.2和cd3的抗体构建体
|
|
KR20210052494A
(ko)
|
2018-08-27 |
2021-05-10 |
아피메트 게엠베하 |
항체 구조물이 사전 로드된 동결 보존된 nk 세포
|
|
GB2576914A
(en)
*
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
|
CA3136478A1
(en)
|
2019-06-05 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
TWI874409B
(zh)
|
2019-06-13 |
2025-03-01 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
|
AU2020345787A1
(en)
|
2019-09-10 |
2022-03-24 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
|
|
EP4058485A1
(en)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
US11926672B2
(en)
|
2019-12-20 |
2024-03-12 |
Amgen Inc. |
Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
|
WO2021130383A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
|
CA3175275A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
|
JP2023527293A
(ja)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
Ｍａｇｅｂ２結合構築物
|
|
CA3183693A1
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
|
CA3187272A1
(en)
|
2020-10-08 |
2022-04-14 |
Thorsten Ross |
Trispecific binders
|
|
CA3198064A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
EP4240767A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
|
CR20230235A
(es)
|
2020-11-06 |
2023-10-05 |
Amgen Res Munich Gmbh |
Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
|
|
CA3205586A1
(en)
|
2020-12-16 |
2022-06-23 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
AR125290A1
(es)
|
2021-04-02 |
2023-07-05 |
Amgen Inc |
Construcciones de unión a mageb2
|
|
US20240384006A1
(en)
|
2021-05-06 |
2024-11-21 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
EP4376958A1
(en)
|
2021-07-30 |
2024-06-05 |
Affimed GmbH |
Duplexbodies
|
|
AU2022381918A1
(en)
|
2021-11-03 |
2024-06-13 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
TW202510911A
(zh)
|
2023-06-14 |
2025-03-16 |
美商安進公司 |
Ｔ細胞接合劑掩蔽分子
|